Model Informed Drug Development Archives

Video

Early Feasibility Assessment (EFA) with Certara IQ™

Learn how Certara IQ performs early feasibility assessments (EFA) to predict biotherapeutic dosing, guide candidate…

CertaraOctober 16, 2025

Video

Certara IQ™: Predicting Recommended Phase 2 Doses with Confidence

Learn how Certara IQ predicts recommended Phase 2 doses using advanced QSP modeling workflows that…

CertaraOctober 16, 2025

Video

Certara IQ™: Model-Informed First-In-Human (FIH) Dose Selection

Discover how Certara IQ uses QSP modeling to predict safe and effective First-In-Human doses, accelerating…

CertaraOctober 16, 2025

Video

Inside Certara IQ™: Building the Future of QSP with Josh Apgar & Chris Bouton

Hear from Certara experts on how Certara IQ modernizes QSP modeling with AI, collaboration tools,…

CertaraOctober 16, 2025

Publication

Effective Visualizations Using “vachette” to Assess and Communicate Pharmacometric Model Results

Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…

Danielle PillsburyOctober 15, 2025

Conference

ICAComP 2025

CertaraOctober 8, 2025

Guide

MBMA vs. Meta-Analysis: Quick Comparison Guide

Discover how Model-Based Meta-Analysis (MBMA) outperforms traditional meta-analysis in drug development by predicting outcomes, informing…

CertaraOctober 8, 2025

Conference

Dutch Medicines Days

CertaraOctober 7, 2025

White Paper

C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions

Replace TQT studies with validated C-QT analysis strategies accepted by FDA, EMA, PMDA. Learn more…

CertaraOctober 3, 2025

Case Study

Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer

Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…

CertaraOctober 2, 2025

Model Informed Drug Development

Early Feasibility Assessment (EFA) with Certara IQ™

Certara IQ™: Predicting Recommended Phase 2 Doses with Confidence

Certara IQ™: Model-Informed First-In-Human (FIH) Dose Selection

Inside Certara IQ™: Building the Future of QSP with Josh Apgar & Chris Bouton

Effective Visualizations Using “vachette” to Assess and Communicate Pharmacometric Model Results

ICAComP 2025

MBMA vs. Meta-Analysis: Quick Comparison Guide

Dutch Medicines Days

C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions

Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer

Newsletter sign up

Quick links

Solutions

Contact